15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Zebrafish expressing human PAX3 and FOXO1 could be used to screen therapies for rhabdomyosarcoma. Zebrafish harboring M214K-mutant p53, engineered to express human PAX3 and FOXO1 and injected with a ubiquitous promoter developed...
16:22 , Jul 11, 2018 |  BC Innovations  |  Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
22:43 , Jun 5, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer An RNA-targeting small molecule that cleaves miR-96 could help treat triple-negative breast cancer (TNBC). The compound consists of a short poly(A) oligionucleotide linked to a small molecule that selectively binds the oncogenic precursor...
22:25 , Dec 18, 2017 |  BC Extra  |  Preclinical News

IL-18 secreting CAR T cells enhance immune killing of tumors

In a paper published in Cell Reports, researchers at the University of Cologne showed that a chimeric antigen receptor (CAR) T cell engineered to release IL-18 converts the CAR T cell to a proinflammatory T...
22:58 , Nov 30, 2017 |  BC Innovations  |  Translation in Brief

Two faces of FOXO1

Columbia University and AstraZeneca plc (LSE:AZN; NYSE:AZN) have identified the first FOXO1 inhibitors that can selectively block the transcription factor’s glucose-stimulating activity without inducing lipogenesis. Optimization of the compounds could yield a therapy for Type...
21:55 , Oct 26, 2017 |  BC Innovations  |  Translation in Brief

Transient nanotargeting

A team from the Fred Hutchinson Cancer Research Center has designed nanoparticles that introduce mRNA cargo to therapeutic cells in vitro, without requiring special instrumentation or causing the cell depletion or cytotoxicity that limits the...
20:06 , Oct 24, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Nanoparticles; cell therapy Nanoparticles loaded with mRNA could be used for ex vivo programming of patient-derived CAR T cells as cancer therapies. The nanoparticles consist of a biodegradable poly(β-amino ester) polymer core loaded with synthetic...
07:00 , May 19, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MicroRNA-96 (miR-96)

Cancer INDICATION: Breast cancer In vitro studies identified an miR-96 inhibitor that could help treat breast cancer. In silico drug design and optimization of a benzimidazole-based miR-96 inhibitor identified a heterodimer consisting of the inhibitor plus another...
07:00 , Apr 28, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: microRNA-3188 (MIR3188); forkhead box O1 (FOXO1)

Cancer INDICATION: Nasopharyngeal cancer Patient sample, cell culture and mouse studies suggest promoting expression of MIR3188 or FOXO1 could help treat nasopharyngeal carcinoma (NPC). In patients, low tumor levels of MIR3188 correlated with large tumor volume and...
07:00 , Apr 14, 2016 |  BC Innovations  |  Product R&D

AACR by the numbers

See Figure: Top indications See Table: Novel cancer targets at AACR 2016 See Figure: Top institutions and companies See Figure: Top targets Tables Novel cancer targets at...